A Phase II Study of Yttrium-90-Labeled Anti-CD20 Monoclonal Antibody [Ibritumomab-tiuxetan-Y-90] in Combination With High-Dose Beam (BCNU [carmustine], Etoposide, Cytarabine and Melphalan) Followed by Autologous Stem Cell Transplantation for Patients With Poor Risk/Relapsed B-Cell Lymphoma.

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 18 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carmustine; Cytarabine; Etoposide; Ibritumomab tiuxetan; Melphalan; Rituximab
Indications Diffuse large B cell lymphoma; Follicular lymphoma; Lymphoma; Mantle-cell lymphoma
Focus Adverse reactions; Therapeutic Use

Most Recent Events

06 Jul 2018 Biomarkers information updated
05 Apr 2012 Planned number of patients changed from 108 to 118 as reported by ClinicalTrials.gov.
09 Jul 2008 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight